THAC is ready to perform a clinical proof of concept phase II in diabetic patients with acute treatment to validate benefit on insulin resistance markers.
In parallel preclinical studies are on-going to validate the use of ALF-5755 in long term administration prior to start clinical phases on type II diabetic patients
